HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anderson J Ryan Selected Research

bisbenzimide ethoxide trihydrochloride (Hoechst 33342)

10/2012Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.
7/2011Investigating temporal fluctuations in tumor vasculature with combined carbogen and ultrasmall superparamagnetic iron oxide particle (CUSPIO) imaging.
11/2009The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
12/2008Longitudinal in vivo susceptibility contrast MRI measurements of LS174T colorectal liver metastasis in nude mice.
11/2007Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126.
5/2005Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Anderson J Ryan Research Topics

Disease

42Neoplasms (Cancer)
01/2021 - 06/2002
11Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2020 - 01/2006
11Necrosis
10/2012 - 06/2002
7Lung Neoplasms (Lung Cancer)
01/2021 - 02/2007
7Neoplasm Metastasis (Metastasis)
09/2009 - 09/2004
6Colorectal Neoplasms (Colorectal Cancer)
05/2019 - 03/2008
6Thyroid Neoplasms (Thyroid Cancer)
01/2014 - 06/2004
5Hypoxia (Hypoxemia)
01/2016 - 12/2008
3Prolactinoma (Prolactinomas)
11/2007 - 03/2004
2Breast Neoplasms (Breast Cancer)
01/2022 - 01/2019
2Body Weight (Weight, Body)
01/2021 - 01/2019
2Vascular Remodeling
09/2017 - 10/2012
2Glioma (Gliomas)
10/2012 - 11/2005
2Adenoma (Adenomas)
10/2012 - 10/2010
2Exanthema (Rash)
01/2012 - 09/2009
2Hypertension (High Blood Pressure)
01/2012 - 11/2007
2Diarrhea
01/2012 - 09/2009
2Disease Progression
01/2012 - 05/2009
2Intestinal Neoplasms (Intestinal Cancer)
10/2010 - 03/2008
2Colonic Neoplasms (Colon Cancer)
09/2010 - 03/2006
2Carcinoma (Carcinomatosis)
11/2009 - 12/2002
2Pancreatic Neoplasms (Pancreatic Cancer)
06/2007 - 10/2005
2Lymphatic Metastasis
06/2007 - 10/2005
1Body Weight Changes
01/2021
1Fibrosis (Cirrhosis)
01/2020
1Liver Neoplasms (Liver Cancer)
01/2020
1Triple Negative Breast Neoplasms
01/2019
1Carcinogenesis
03/2018
1Prostatic Neoplasms (Prostate Cancer)
08/2017
1Starvation
11/2015
1Pathologic Neovascularization
09/2015
1Gastrointestinal Neoplasms (Gastrointestinal Cancer)
10/2012
1Nausea
01/2012
1Headache (Headaches)
01/2012
1medullary Thyroid cancer
01/2012

Drug/Important Bio-Agent (IBA)

23vandetanib (ZD6474)IBA
01/2014 - 12/2002
12N-acetylcochinol-O-phosphateIBA
11/2007 - 06/2002
11ErbB Receptors (EGF Receptor)IBA
03/2014 - 12/2002
10Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
09/2015 - 09/2004
9Biomarkers (Surrogate Marker)IBA
09/2017 - 05/2005
7Tyrosine Kinase InhibitorsIBA
07/2014 - 12/2002
6bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA
10/2012 - 05/2005
6Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
02/2011 - 12/2002
6Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
05/2009 - 09/2004
5Pharmaceutical PreparationsIBA
01/2021 - 06/2004
5Gefitinib (Iressa)FDA Link
07/2014 - 05/2009
4DNA (Deoxyribonucleic Acid)IBA
01/2021 - 10/2012
4Proteins (Proteins, Gene)FDA Link
08/2017 - 07/2013
4ferumoxtran-10 (ultrasmall superparamagnetic iron oxide)IBA
10/2012 - 11/2007
4Phosphotransferases (Kinase)IBA
10/2012 - 06/2004
4Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
07/2011 - 11/2005
4Paclitaxel (Taxol)FDA LinkGeneric
01/2010 - 04/2005
4Epidermal Growth Factor (EGF)IBA
03/2008 - 12/2002
3Poly(ADP-ribose) Polymerase InhibitorsIBA
05/2019 - 01/2016
3Histones (Histone)IBA
11/2015 - 10/2012
3GemcitabineFDA Link
01/2014 - 10/2005
3N-acetylcolchinolIBA
11/2007 - 03/2004
2Urethane (Ethyl Carbamate)IBA
01/2021 - 01/2019
2olaparibIBA
01/2021 - 01/2016
21,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA
01/2021 - 01/2016
2CytokinesIBA
03/2018 - 01/2010
2Radiation-Sensitizing AgentsIBA
01/2018 - 01/2016
2Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
01/2018 - 01/2016
2cediranib (AZD2171)IBA
11/2015 - 10/2012
2carbogenIBA
10/2012 - 07/2011
2pimonidazoleIBA
10/2012 - 12/2008
2Carboplatin (JM8)FDA LinkGeneric
01/2010 - 05/2009
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
11/2009 - 02/2007
2Phosphates (Orthophosphate)IBA
11/2007 - 03/2004
1xentuzumabIBA
01/2022
1Doxorubicin (Adriamycin)FDA LinkGeneric
01/2020
1lysyl- arginyl- alanyl- lysyl- alanyl- lysyl- threonyl- threonyl- lysyl- lysyl- arginine (PKCS)IBA
01/2020
1DNA-Activated Protein KinaseIBA
01/2020
1Topoisomerase InhibitorsIBA
01/2020
1midostaurinIBA
03/2018
1talazoparibIBA
01/2018
1Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
09/2017
1Protein Kinases (Protein Kinase)IBA
08/2017
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
08/2017
1Caspase 3 (Caspase-3)IBA
01/2016
1Carbonic Anhydrase IXIBA
01/2016
1adavosertibIBA
11/2015
1Chloroquine (Aralen)FDA LinkGeneric
07/2014
1Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2014
1NucleosidesIBA
01/2014
1UridineIBA
01/2014
1HeterochromatinIBA
12/2013
1ProdrugsIBA
10/2012
12- ((3- ((4- ((5- (2- ((3- fluorophenyl)amino)- 2- oxoethyl)- 1H- pyrazol- 3- yl)amino)quinazolin- 7- yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphateIBA
10/2012
1Aurora Kinase BIBA
10/2012
1AZD 1152-HQPAIBA
10/2012
1vatalanib (PTK787)IBA
07/2011
1SodiumIBA
10/2010
1Drinking WaterIBA
10/2010

Therapy/Procedure

13Therapeutics
01/2022 - 09/2004
6Radiotherapy
01/2021 - 03/2014
4Aftercare (After-Treatment)
10/2012 - 05/2005
3Drug Therapy (Chemotherapy)
01/2020 - 01/2010
1Chemoradiotherapy
11/2020
1Intravenous Administration
07/2011